London- On Wednesday, Europe’s medicines regulator exclaimed that it still believes the benefits of Johnson & Johnson’s Covid-19 vaccine outweigh the risks for side effects by following reports of extremely which is rare blood clotting.
However, it comes shortly after the U.S. Food and Drug Administration informed the states to temporarily pause by using J&J’s vaccine “out of an abundance of caution” after six cases of a blood-clotting disorder who were detected within 6.8 million doses of shot.
However, all six cases took place in the U.S. in women aged between 18 and 48, with symptoms developing six to 13 days after receiving the shot. Notably, FDA mentioned as one woman who died as a result of blood clot complications and the other is in critical condition.
Moreover, the European Medicines Agency mentioned it is currently investigating all the reported cases and will be decided whether the regulatory action is needed.
Europe’s medicines regulator mentioned in a statement, “The EMA is currently expediting this evaluation and currently expects to issue a recommendation next week. While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.”
Currently, South Africa has halted its rollout of the shots which J&J mentioned it would “proactively delay” deliveries of its vaccine to Europe which began in the last week. However, the vaccine was authorized in the EU on 11th March but the widespread utilization of the shot yet didn’t start.
On Tuesday, “Right now, these adverse events appear to be extremely rare. COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously.”
Within the last week, Europe’s medicines regulators mentioned it found a possible link between the coronavirus vaccine which is developed by AstraZeneca, and the University of Oxford, and rare blood-clotting glitches. Now, AstraZeneca yet didn’t receive authorization for the utilization in the U.S.
Moreover, the Oxford-AstraZeneca and J&J vaccines work in similar ways and both utilize an adenovirus, a common type of virus that typically causes mild cold symptoms.
